Dr Pedro Cano, MD, MBA

Dr. Pedro Cano received his MD from the Universidad de Murcia School of Medicine in Murcia, Spain, and his MBA from the University of Chicago, Graduate School of Business (Economics and Statistics). He completed a fellowship in transfusion medicine and postgraduate fellowship in molecular immunology, HLA typing laboratory at the Blood Center of Southeastern Wisconsin and Medical College of Wisconsin Affiliated Hospitals. Following his fellowships he was an Assistant Professor at the University of Maryland School of Medicine, Baltimore, and Associate Director, Transfusion Medicine Service and Hematology Laboratory, University of Maryland Medical System (1994-2000); Assistant Professor in the Department of Laboratory Medicine at the University of Texas, MD Anderson Cancer Center (2000-2004). He was promoted to Clinical Associate Professor in the Department of Laboratory Medicine, Division of Pathology/Laboratory Medicine, at the University of Texas MD Anderson Cancer Center, Houston …(2004-2015) and served as Medical Director, Department of Laboratory Medicine, Division of Pathology/Laboratory Medicine, HLA Typing Laboratory. He is currently a Senior Member in the Department of Hematopathology and Laboratory Medicine at H. Lee Moffitt Cancer Center and Research Institute, and serves as the Medical Director of the HLA Laboratory. Dr. Cano is both nationally and internationally recognized as an expert in HLA immunogenetics and has been integral to the development of ASHI standards for clinical testing. His clinical focus is the analysis of immunogenetics data in hematopoietic stem cell transplantation, and to this end has developed software for the interpretation and reporting of HLA results in the EHR. He is also interested in the use of automation in the high-complexity clinical laboratory and the management of information in the clinical laboratory. His research interests include 1) the use of population genetics in the interpretation of HLA genotyping results, 2) the characterization of HLA epitopes in terms of DNA and protein sequence properties, and 3) the selections of peptides for their presentation to T cells by the HLA molecule.